Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > 💡A better Buy ~ SHRM Champignon Brands🔋🍄🌪

<< Previous

Bullboard Posts

Next >>

Comment by Covid19on Apr 27, 2021 4:23pm

327 Views

Post# 33076409

RE:💡A better Buy ~ SHRM Champignon Brands🔋🍄🌪

initforthemush wrote: "The stress of the COVID-19 pandemic has been unprecedented, and it has highlighted the need to provide novel treatments for individuals suffering from depression. We are well positioned to be a leader in both implementing rapid-acting ketamine/esketamine-based treatments for depression and discovering innovative future treatments for persons affected by depression." "We are pleased to be moving forward with a strengthened team and focus on governance. We have successfully advanced our business strategy to establish a network of clinics designed to provide rapid-acting treatments for adults with depression," said Dr. Roger McIntyre, Chairman and CEO.

The stress of the COVID-19 pandemic has been unprecedented, and it has highlighted the need to provide novel treatments for individuals suffering from depression. We are well positioned to be a leader in both implementing rapid-acting ketamine/esketamine-based treatments for depression and discovering innovative future treatments for persons affected by depression." "We are pleased to be moving forward with a strengthened team and focus on governance. We have successfully advanced our business strategy to establish a network of clinics designed to provide rapid-acting treatments...

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”